Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 8/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | CALML3 | P27482 | 1/20 | 0.41 |
| ▸ | SDHA | P31040 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.37 |
| ▸ | GPR6 | P46095 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3394857 | 0.91 | MAOB (0.47) | MAOBMAPTMAOAKMT2ALMNA | |
| SCHEMBL3396451 | 0.88 | MAOB (0.45) | MAOBMAPTMAOAKMT2ALMNA | |
| SCHEMBL3395525 | 0.88 | KMT2A (0.46) | MAOBMAPTMAOAKMT2ALMNA | |
| SCHEMBL3397716 | 0.86 | MAOB (0.45) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3394642 | 0.85 | MAOB (0.49) | MAOBMAPTMAOAKMT2ALMNA | |
| SCHEMBL3392749 | 0.84 | MAOB (0.47) | MAOBMAPTMAOAKMT2ALMNA | |
| SCHEMBL3395668 | 0.83 | MAOB (0.50) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3419157 | 0.83 | MAOB (0.45) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3396915 | 0.83 | MAOB (0.52) | MAOBMAOALMNAPTGS1CALML3 | |
| SCHEMBL3394838 | 0.83 | MAOB (0.51) | MAOBMAOALMNAPTGS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | claimed |
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234390-A1 | NOVEL COMPOUND AND THEIR USE | HTRA1, PRSS1, PRNP | MAOB 2054/4885MAPT 62/4885MAOA 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.